These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38480595)

  • 1. Linezolid-Induced Thrombocytopenia in Patients with Renal Impairment: A Case Series, Review and Dose Advice.
    Laarhuis SRE; Kerskes CHM; Nijziel MR; van Wensen RJA; Touw DJ
    Drugs R D; 2024 Mar; 24(1):109-115. PubMed ID: 38480595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.
    Crass RL; Cojutti PG; Pai MP; Pea F
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
    Kawasuji H; Tsuji Y; Ogami C; Kimoto K; Ueno A; Miyajima Y; Kawago K; Sakamaki I; Yamamoto Y
    BMC Pharmacol Toxicol; 2021 Mar; 22(1):13. PubMed ID: 33663616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linezolid-Associated Thrombocytopenia in Children With Renal Impairment.
    Jones SJ; Nichols KR; DeYoung HL; Cox EG; Knoderer CA
    J Pediatric Infect Dis Soc; 2015 Sep; 4(3):272-5. PubMed ID: 26407433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of vancomycin or linezolid therapy on development of renal dysfunction and thrombocytopenia in Japanese patients.
    Fujii S; Takahashi S; Makino S; Kunimoto Y; Nakata H; Noda N; Sakurai K; Miyamoto A
    Chemotherapy; 2013; 59(5):319-24. PubMed ID: 24480883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy.
    Niwa T; Suzuki A; Sakakibara S; Kasahara S; Yasuda M; Fukao A; Matsuura K; Goto C; Murakami N; Itoh Y
    Clin Ther; 2009 Oct; 31(10):2126-33. PubMed ID: 19922883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases.
    Choi GW; Lee JY; Chang MJ; Kim YK; Cho Y; Yu YM; Lee E
    Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):228-234. PubMed ID: 30171804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.
    Nukui Y; Hatakeyama S; Okamoto K; Yamamoto T; Hisaka A; Suzuki H; Yata N; Yotsuyanagi H; Moriya K
    J Antimicrob Chemother; 2013 Sep; 68(9):2128-33. PubMed ID: 23625638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature.
    Cossu AP; Musu M; Mura P; De Giudici LM; Finco G
    Eur J Clin Pharmacol; 2014 Jan; 70(1):23-8. PubMed ID: 24022332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A standard dose of linezolid puts patients with hepatic impairment at risk of overexposure.
    Liao R; Dong Y; Chen L; Wang T; Li H; Dong H
    Eur J Clin Pharmacol; 2023 Jan; 79(1):149-157. PubMed ID: 36434292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients.
    Dai Y; Jiang S; Chen X; Han L; Zhang C; Yu X; Zhang X
    J Clin Pharm Ther; 2021 Jun; 46(3):807-813. PubMed ID: 33555057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study.
    Cojutti PG; Merelli M; Bassetti M; Pea F
    J Antimicrob Chemother; 2019 Dec; 74(12):3588-3595. PubMed ID: 31504570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study.
    Kim HS; Lee E; Cho YJ; Lee YJ; Rhie SJ
    J Clin Pharm Ther; 2019 Feb; 44(1):84-90. PubMed ID: 30243033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia.
    Hanai Y; Matsuo K; Ogawa M; Higashi A; Kimura I; Hirayama S; Kosugi T; Nishizawa K; Yoshio T
    J Infect Chemother; 2016 Aug; 22(8):536-42. PubMed ID: 27321773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis.
    Zhang D; Xu Y; Wang X; Hou L; Xing M; Xu S; Guo R; Luo Y
    Eur J Clin Pharmacol; 2023 Oct; 79(10):1303-1314. PubMed ID: 37578552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosage regimen and toxicity risk assessment of linezolid in sepsis patients.
    Dou L; Meng D; Dong Y; Chen L; Han X; Fan D; Dong H
    Int J Infect Dis; 2020 Jul; 96():105-111. PubMed ID: 32251797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
    Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid.
    Zhang YM; Yu W; Zhou N; Li JZ; Xu LC; Xie ZY; Lu YF; Li LJ
    Hepatobiliary Pancreat Dis Int; 2015 Jun; 14(3):287-92. PubMed ID: 26063030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics.
    Rao GG; Konicki R; Cattaneo D; Alffenaar JW; Marriott DJE; Neely M;
    Ther Drug Monit; 2020 Feb; 42(1):83-92. PubMed ID: 31652190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis.
    Ichie T; Suzuki D; Yasui K; Takahashi H; Matsuda M; Hayashi H; Sugiura Y; Sugiyama T
    J Clin Pharm Ther; 2015 Jun; 40(3):279-84. PubMed ID: 25732525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.